Large R&D-based companies
GSK leads the group in 2020, followed closely by Pfizer and Johnson & Johnson. Shionogi has moved up into third, in front of Novartis and Otsuka. All companies in this group take diverse action to limit AMR. However, only a few continue to expand efforts to safeguard this critical area of modern medicine.
Generic medicine manufacturers
Cipla, Teva and Fresenius Kabi take the lead in this group in 2020. All three are implementing policies that will help ensure antibacterial and antifungal medicines are promoted responsibly. Against a backdrop of greater disclosure, the leaders in this group are reported as taking additional steps against AMR compared to 2018.
Entasis leads in 2020, followed closely by Wockhardt. Three leaders stand out for targeting bacteria in the highest threat category defined by WHO and the CDC, and for supporting late-stage projects with plans to ensure better access and good stewardship soon after launch. Transparency in this group has improved since 2018.